Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499594 | 1.00 | OPRL1 (0.56) | OPRL1KCNH2OPRM1CCR5CHRM4 | |
| SCHEMBL6499591 | 1.00 | OPRL1 (0.56) | OPRL1KCNH2OPRM1CCR5CHRM4 | |
| Hydrochloric Acid SCHEMBL6501071 | 0.99 | OPRL1 (0.55) | OPRL1KCNH2OPRM1CCR5CHRM4 | |
| Hydrochloric Acid SCHEMBL6501066 | 0.99 | OPRL1 (0.55) | OPRL1KCNH2OPRM1CCR5CHRM4 | |
| SCHEMBL6489330 | 0.88 | OPRL1 (0.59) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6490537 | 0.88 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6491806 | 0.88 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6492943 | 0.88 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6490539 | 0.88 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6504327 | 0.87 | OPRL1 (0.56) | OPRL1KCNH2OPRM1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | claimed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | claimed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | OPRL1 9/4885KCNH2 706/4885OPRM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.